Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Tim C.P. Somervaille"'
Autor:
Revathy Ramachandran, Shakhzada Ibragimova, Laura M. Woods, Tamader AlHouqani, Roshna Lawrence Gomez, Fabrizio Simeoni, Mahmood Y. Hachim, Tim C.P. Somervaille, Anna Philpott, Jason S. Carroll, Fahad R. Ali
Publikováno v:
iScience, Vol 27, Iss 8, Pp 110500- (2024)
Summary: Triple-negative breast cancer (TNBC) is characterized by lack of the estrogen (ER) receptor, progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and standard receptor-targeted therapies are ineffective. FOXC1, a
Externí odkaz:
https://doaj.org/article/95f276360fa1442aa803bad570a00ca8
Autor:
Francesco Camera, Isabel Romero-Camarero, Bradley H. Revell, Fabio M.R. Amaral, Oliver J. Sinclair, Fabrizio Simeoni, Daniel H. Wiseman, Lovorka Stojic, Tim C.P. Somervaille
Publikováno v:
iScience, Vol 26, Iss 8, Pp 107319- (2023)
Summary: Iroquois transcription factor gene IRX3 is highly expressed in 20–30% of acute myeloid leukemia (AML) and contributes to the pathognomonic differentiation block. Intron 8 FTO sequences ∼220kB downstream of IRX3 exhibit histone acetylatio
Externí odkaz:
https://doaj.org/article/dac1ea7a14724c488dbf13c5dafe5783
Autor:
Fabrizio Simeoni, Isabel Romero-Camarero, Francesco Camera, Fabio M.R. Amaral, Oliver J. Sinclair, Evangelia K. Papachristou, Gary J. Spencer, Michael Lie-A-Ling, Georges Lacaud, Daniel H. Wiseman, Jason S. Carroll, Tim C.P. Somervaille
Publikováno v:
Cell Reports, Vol 36, Iss 12, Pp 109725- (2021)
Summary: Despite absent expression in normal hematopoiesis, the Forkhead factor FOXC1, a critical mesenchymal differentiation regulator, is highly expressed in ∼30% of HOXAhigh acute myeloid leukemia (AML) cases to confer blocked monocyte/macrophag
Externí odkaz:
https://doaj.org/article/03d3a10c03eb467b9558377392816f96
Autor:
Alba Maiques-Diaz, Gary J. Spencer, James T. Lynch, Filippo Ciceri, Emma L. Williams, Fabio M.R. Amaral, Daniel H. Wiseman, William J. Harris, Yaoyong Li, Sudhakar Sahoo, James R. Hitchin, Daniel P. Mould, Emma E. Fairweather, Bohdan Waszkowycz, Allan M. Jordan, Duncan L. Smith, Tim C.P. Somervaille
Publikováno v:
Cell Reports, Vol 22, Iss 13, Pp 3641-3659 (2018)
Summary: Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1’s histone demethylase activity.
Externí odkaz:
https://doaj.org/article/62c57f81e288426abeec246fcdba9441
Autor:
Tim D.D. Somerville, Fabrizio Simeoni, John A. Chadwick, Emma L. Williams, Gary J. Spencer, Katalin Boros, Christopher Wirth, Eleni Tholouli, Richard J. Byers, Tim C.P. Somervaille
Publikováno v:
Cell Reports, Vol 22, Iss 3, Pp 638-652 (2018)
The Iroquois homeodomain transcription factor gene IRX3 is expressed in the developing nervous system, limb buds, and heart, and transcript levels specify obesity risk in humans. We now report a functional role for IRX3 in human acute leukemia. Altho
Externí odkaz:
https://doaj.org/article/4afa71a0ca914ca1a316ea4f6f7850b2
Publikováno v:
HemaSphere, Vol 3, Iss 3 (2019)
Abstract. Myeloproliferative neoplasms (MPN) are clonal stem cell associated disorders inclusive of chronic myeloid leukemia (CML), Polycythaemia vera (PV), myelofibrosis (MF), and essential thrombocythemia (ET). They are characterized by increased p
Externí odkaz:
https://doaj.org/article/a6171f4d99754bf6b8fd7dd80fe99025
Publikováno v:
Molecular & Cellular Oncology, Vol 5, Iss 4 (2018)
Pharmacologic inhibition of KDM1A (Lysine Demethylase 1A) induces differentiation in certain subtypes of acute myeloid leukemia. Our recent studies reveal this is dependent upon drug-induced disruption of the GFI1 (Growth Factor Independent 1) transc
Externí odkaz:
https://doaj.org/article/54c03ffaaa5844b88e4542acc79a378c
Autor:
Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, Pau Montesinos
Publikováno v:
Blood. 140:1711-1713
Autor:
Alexandros Rampotas, Luke Carter-Brzezinski, Tim C.P Somervaille, James Forryan, Bethan Psaila, Adam J Mead, Mamta Garg, Heather Laing, Louise Wallis, Nauman M Butt, Conal McConville, Ali Sahra, Andrew McGregor, Hannah Cowan, Andrew J. Innes, Joanne Ewing, Matthew Carter, Peter Dyer, Chun Huat Teh, Sebastian Francis, Frances Wadelin, Claire Harrison, Anna L Godfrey, Elizabeth Kulakov, Donal P. McLornan, Jonathan Lambert
Publikováno v:
Blood. 140:9721-9723
Autor:
Claire N. Harrison, Jacqueline S. Garcia, Tim C.P. Somervaille, James M. Foran, Srdan Verstovsek, Catriona Jamieson, Ruben Mesa, Ellen K. Ritchie, Srinivas K. Tantravahi, Pankit Vachhani, Casey L. O'Connell, Rami S. Komrokji, Jason Harb, Jessica E. Hutti, Leanne Holes, Abdullah A. Masud, Silpa Nuthalapati, Jalaja Potluri, Naveen Pemmaraju
Publikováno v:
Journal of Clinical Oncology. 40:1671-1680
PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy and safety of adding BCL-XL/BCL-2 inhibitor navitoclax to ruxolitinib